One of the most important clinical utilities of S1823 is essentially that we can use microRNA371 to mold our active surveillance. Based on the time of relapse that we observed in patients enrolled in S1823, we know that it’s much shorter than what we knew from historical and retrospective studies. So in my view, we can use microRNA371 to intensify the active surveillance using microRNA371, especially in the first six months from diagnosis, and to hopefully detect the relapse soon and early enough to avoid chemotherapy, but still cure our patients...
One of the most important clinical utilities of S1823 is essentially that we can use microRNA371 to mold our active surveillance. Based on the time of relapse that we observed in patients enrolled in S1823, we know that it’s much shorter than what we knew from historical and retrospective studies. So in my view, we can use microRNA371 to intensify the active surveillance using microRNA371, especially in the first six months from diagnosis, and to hopefully detect the relapse soon and early enough to avoid chemotherapy, but still cure our patients. I wouldn’t necessarily envision using this test to inform chemotherapy, adjuvant chemotherapy, because we don’t really know if the microRNA is only one positive, should be considered as metastatic patients, so deliver the full package of three cycles, or can be considered as adjuvant patients, so deliver one or two cycles. But what we know is that if we can detect the relapse early enough, so in a stage that is less than three centimeters on ilioinguinal nodes, we can definitely cure these patients avoiding chemotherapy, with surgery, for example.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
